Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaginal sarcoma: the Royal Marsden experience.

H.Y.S. Ngan1, C. Fisher, P. Blake

  • 1Department of Gynaecology, Department of Pathology and Department of Radiotherapy, Royal Marsden Hospital, London, UK.

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|September 1, 1994
PubMed
Summary

Vaginal sarcoma has a poor prognosis, but early stage and low-grade tumors offer better survival. Late recurrences can occur, and current treatments are ineffective for advanced or recurrent vaginal sarcoma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Further evaluation of reproducibility and prognostic value of histologic typing and grading in FIGO stage I ovarian cancer patients without systemic locoregional adjuvant treatment.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·1995
Same author

Problems in the use of urinary hCG-beta-core as a tumor marker in gynecologic cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·1995
Same author

Multiparameter flow cytometric measurement of epidermal growth factor receptor and c-erbB-2 oncoprotein in cultured cells and in fresh and preserved solid tumor cells.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·1995
Same author

Multivariate analysis of factors affecting survival in pelvic exenteration.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·1994
Same author

Malignant melanoma of the vulva and vagina: a report of 23 cases presenting in a 10-year period.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·1994
Same author

Treatment of advanced carcinoma of the vulva with chemoradiotherapy - can exenterative surgery be avoided?

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·1994

Area of Science:

  • Gynecologic Oncology
  • Surgical Pathology
  • Cancer Prognosis

Background:

  • Vaginal sarcoma is a rare malignancy with a historically poor prognosis.
  • Limited data exists on prognostic factors and effective treatment strategies.

Purpose of the Study:

  • To review clinicopathologic features of vaginal sarcoma.
  • To identify prognostic indicators for patient survival.
  • To evaluate treatment efficacy for advanced or recurrent disease.

Main Methods:

  • Retrospective clinicopathologic review of six patients with vaginal sarcoma.
  • Analysis of tumor stage, grade, and patient outcomes.
  • Assessment of treatment responses to chemotherapy and radiotherapy.

Related Experiment Videos

Main Results:

  • Three of six patients achieved 5-year survival, all with early-stage, low-to-intermediate grade tumors.
  • Tumor stage and grade were significant prognostic factors.
  • Late recurrences were observed in two long-term survivors (5 and 21 years).
  • Chemotherapy and radiotherapy showed no benefit in advanced or recurrent disease.

Conclusions:

  • Early stage and lower tumor grade are critical for favorable outcomes in vaginal sarcoma.
  • Vaginal sarcoma prognosis remains poor, with a risk of late recurrences.
  • Current systemic and radiation therapies are ineffective for advanced or recurrent vaginal sarcoma.